Last reviewed · How we verify
Cholestyramine Powder
Cholestyramine is an anion exchange resin that binds bile acids in the intestine, preventing their reabsorption and increasing fecal excretion.
Cholestyramine is an anion exchange resin that binds bile acids in the intestine, preventing their reabsorption and increasing fecal excretion. Used for Hypercholesterolemia, Pruritus associated with biliary obstruction.
At a glance
| Generic name | Cholestyramine Powder |
|---|---|
| Also known as | Questran |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Drug class | Bile acid sequestrant |
| Target | Bile acids |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By binding bile acids in the gastrointestinal tract, cholestyramine prevents their enterohepatic circulation and reabsorption. This forces the liver to synthesize new bile acids from cholesterol, thereby reducing serum cholesterol levels. The drug also reduces LDL cholesterol and can lower triglycerides in some patients.
Approved indications
- Hypercholesterolemia
- Pruritus associated with biliary obstruction
Common side effects
- Constipation
- Abdominal discomfort
- Nausea
- Bloating
- Flatulence
Key clinical trials
- Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients (NA)
- Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease (PHASE2)
- Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism (PHASE3)
- Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale (PHASE4)
- Low Doses of Cholestyramine in the Treatment of Hyperthyroidism (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cholestyramine Powder CI brief — competitive landscape report
- Cholestyramine Powder updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Nice portfolio CI